<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01330758</url>
  </required_header>
  <id_info>
    <org_study_id>D0102C00005</org_study_id>
    <nct_id>NCT01330758</nct_id>
  </id_info>
  <brief_title>A Study to Compare Two Different Tablet Formulations of AZD8931 in Healthy Males and Females</brief_title>
  <official_title>A Phase I, Randomised, Open-label, Cross-over, Single-centre Study in Healthy Male and Non-fertile Female Volunteers to Determine the Relative Bioavailability of the Phase II Wet Granulation Tablet Formulation Compared to the Phase II/III Roller Compacted Tablet Formulation of AZD8931</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to compare two different tablet formulations of AZD8931 in healthy males and females.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the relative bioavailability of 40 mg AZD8931 Phase II wet granulation tablet formulation in relation to the 40mg AZD8931 Phase II/III roller compacted tablet formulation.</measure>
    <time_frame>Pharmacokinetic (PK) sampling will be performed day 1 to day 5 for each treatment period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To further investigate the safety and tolerability variables (adverse events,vital signs, ECG, physical examination, safety labs).</measure>
    <time_frame>From screening period through to 5 to 10 days after visit 3. An average time of 7 weeks.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">26</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>40 mg AZD8931 wet granulation tablet formulation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>40 mg AZD8931 roller compacted tablet formulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD8931</intervention_name>
    <description>40 mg AZD8931 wet granulation tablet formulation</description>
    <arm_group_label>40 mg AZD8931 wet granulation tablet formulation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD8931</intervention_name>
    <description>40 mg AZD8931 roller compacted tablet formulation</description>
    <arm_group_label>40 mg AZD8931 roller compacted tablet formulation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female subjects aged 18 to 55 years

          -  Females must have a negative pregnancy test at screening and on admission to the unit,
             must not be lactating and must be of non-child bearing potential

          -  Body mass index between 19 and 30 kg/m2 and weight at least 50 kg and no more than 100
             kg

          -  Male subjects must be willing to use barrier methods of contraception

          -  Be willing and able to comply with study procedures, restrictions and requirements

        Exclusion Criteria:

          -  History of any clinically significant disease or disorder

          -  Any clinically significant abnormalities at screening

          -  Use of any prescribed or non-prescribed medication within 2 weeks

          -  Receipt of another NCE or participation in any other clinical trial within 3 months

          -  Subjects who have previously received AZD8931
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mary Stuart</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca,1F64, Mereside, Alderley Park, Macclesfield, Cheshire,SK10 4TG UK</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dr Darren Wilbraham, DICP, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Quintiles Drug Research Unit at Guy's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jason Clark, BSc</last_name>
    <role>Study Director</role>
    <affiliation>Quintiles Drug Research Unit at Guy's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 22, 2011</study_first_submitted>
  <study_first_submitted_qc>April 6, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 7, 2011</study_first_posted>
  <last_update_submitted>July 28, 2011</last_update_submitted>
  <last_update_submitted_qc>July 28, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 29, 2011</last_update_posted>
  <responsible_party>
    <name_title>Mary Stuart/Medical Science Director</name_title>
    <organization>AstraZeneca</organization>
  </responsible_party>
  <keyword>Phase I</keyword>
  <keyword>Healthy male and non-fertile female volunteers</keyword>
  <keyword>Bioavailability</keyword>
  <keyword>AZD8931</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

